

# Scancell Holdings PLC

10:30 15 Jan 2018

## Scancell poised for "significant" year with its immuno-oncology portfolio

Skin cancer is the fifth most common cancer in the UK with around 13,000 new cases of melanoma diagnosed annually and 2,000 deaths a year.

In fact, recent studies have found that malignant melanoma diagnoses hit 10,000 a year for over 55s alone, compared with just 3,100 cases two decades ago, an increase of 155%.

Dr Anton Alexandroff, a consultant dermatologist at Leicester Royal Infirmary, said the increase was likely due to "reckless" lifestyles and improper protection from the sun, which is the main cause of most skin cancers.

There is hope for those with this deadly type of cancer though, with Scancell Holdings Plc's (LON:SCLP) SCIB1 immunotherapy **continuing to produce remarkable survival data** from the ongoing phase I/II clinical trial.

### Priming the body to fight cancer

Scancell's immunotherapy vaccine primes the patient's immune system to recognise and kill specific cancer cells.

SCIB1 - and now SCIB2 - targets and stimulates existing cells that make up the body's defence mechanisms, in particular the dendritic cells already present at the site of the cancer.

Dendritic cells are found in all tissues that are in contact with the external environment, such as the skin, lungs and intestines.

The main function of these cells is to process antigens - foreign or toxic material - and present them to the immune system. Once activated, they migrate to the lymph nodes where the antigen is destroyed by the body's T cells.

### "Compelling" clinical trial results so far

At the turn of the year, Scancell reported the "compelling" results of a phase I/II trial of SCIB1, and the immunotherapy has continued to impress since.

Overall, 18 of the 20 stage III/IV melanoma patients with resected disease (i.e. some or all of the tumour has been surgically removed in the past) remain alive and have lived significantly longer than the 'established norms'.

Of the 16 resected patients who received 2-4 milligram (mg) doses of SCIB1, only six patients have had a recurrence of their disease while only two have died.

**READ: SCIB1 continues to produce strong survival data**

**WATCH: CEO Goodfellow discusses recent £5mIn fundraise**

**Price:** 5.65

**Market Cap:** £26.29 m

### 1 Year Share Price Graph



### Share Information

**Code:** SCLP

**Listing:** LSE

**52 week High Low**  
10 4.2

**Sector:** Pharma & Biotech

**Website:** [www.scancell.co.uk](http://www.scancell.co.uk)

### Company Synopsis:

*Cancer remains one of the world's most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body's own natural defence mechanism - the immune system. Scancell's mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.*

action@proactiveinvestors.com

The median observation time for this group of patients is edging up towards five years, with seven patients in the trial surviving for longer than that since starting treatment.

Remarkably, four of those have managed to live for that period without having the disease return.

One patient with unresected disease has also been able to survive for longer than five years since starting treatment with SCIB1 despite the disease progressing.

Two of four resected patients who received stronger 8mg doses of SCIB1 have experienced disease recurrence although none have died, Scancell added.

"We are pleased to report that most patients with resected disease enrolled in the SCIB1 clinical trial are still alive and without disease recurrence, including the majority of patients who were previously undergoing continuation treatment," said chief executive Richard Goodfellow.

### **Next study will be in the States**

Investors have known for a while that next up is a SCIB1/ checkpoint inhibitor combination study which will be carried out in the United States.

A new batch of the drug has been manufactured and will be released for clinical use later this quarter.

That will coincide with the submission of the investigational new drug (IND) application to the US Food and Drug Administration for a phase II trial, which is on track to be submitted before the end of September.

"Our next study, which will be in the US, will assess the potential for an increase in response rate in patients with malignant melanoma when treated with SCIB1 and a checkpoint inhibitor," said Goodfellow.

### **Not just skin cancer treatments though...**

While SCIB1 is furthest along the pipeline, Scancell also has a non-small cell lung cancer (NSCLC) treatment - SCIB2 - which is progressing well.

In November, Cancer Research UK agreed to fund and sponsor a Phase I/II clinical trial of its SCIB2 lung cancer vaccine.

Scancell said the tie-up was a "significant endorsement" of its ImmunoBody platform - the underlying technology behind both SCIB1 and SCIB2 which helps to prime a patient's immune system to recognise and kill specific cancer cells.

Collaborations with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation are already in place.

ALCMI will assist Scancell with the design and development of the study, which is set to get underway this year and complete around 18 months later.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That's more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.

CD4+ another area of collaboration

Another collaboration with European firm BioNTech will focus on the development of T-cell therapies for the treatment of cancer.

Moditope, Scancell's platform, is a new class of potentially potent immunotherapy agent that naturally stimulates the

production of cancer killer CD4+ T cells.

The research will combine the Moditope immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.

At 11.35p, Scancell is valued at £35.9mln.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).